South Korea’s Rokit Announces $3M Grant to Enter 3D Bioprinting Space

We may be in the early stages of a medical revolution, a revolution which changes the way in which medical professionals view and treat numerous ailments. As the fields of robotics, 3D printing, and biological research converge, 3D bioprinting is no longer a technology of the far future, but instead it’s a technology of today. There are already several pharmaceutical companies utilizing Organovo’s ExVive3D bioprinted human liver tissue for drug toxicity testing, and new companies such as BioBots are breaking onto the scene with their own bioprinting approaches. As funding continues to pour into this space, progress will naturally follow.
(...weiter auf 3dprint.com)